A Randomized, Double-Blind, Multicenter, Equivalence Study of ONS-3010 and Humira® for the Treatment of Patients with Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Oncobiologics
- 16 Jun 2016 According to an Oncobiologics media release, the company has received the first of its European Union (EU) clinical trial authorization (CTA) approvals, including in the United Kingdom, Germany and Spain, for the biosimilarity study portion of this trial.
- 01 Jun 2016 Status changed from planning to recruiting.
- 06 May 2015 New trial record